<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Infect Dis</journal-id><journal-title>BMC Infectious Diseases</journal-title><issn pub-type="epub">1471-2334</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2334-7-108</article-id><article-id pub-id-type="pmid">17877801</article-id><article-id pub-id-type="doi">10.1186/1471-2334-7-108</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Common TNF-&#x003b1;, IL-1&#x003b2;, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Jessen</surname><given-names>Kristine Marie</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s021726@student.dtu.dk</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Lindboe</surname><given-names>Sarah Bjerre</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s022073@student.dtu.dk</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Petersen</surname><given-names>Anncatrine Luisa</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>s021932@student.dtu.dk</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Eugen-Olsen</surname><given-names>Jesper</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jeo@biobase.dk</email></contrib><contrib id="A5" corresp="yes" contrib-type="author"><name><surname>Benfield</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>tlb@dadlnet.dk</email></contrib></contrib-group><aff id="I1"><label>1</label>Clinical Research Unit, Hvidovre University Hospital, Copenhagen, Denmark</aff><aff id="I2"><label>2</label>Department of Infectious Diseases, Hvidovre University Hospital, Copenhagen, Denmark</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>18</day><month>9</month><year>2007</year></pub-date><volume>7</volume><fpage>108</fpage><lpage>108</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/7/108"/><history><date date-type="received"><day>27</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>18</day><month>9</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Jessen et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Jessen et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Jessen Marie Kristine s021726@student.dtu.dk </dc:author><dc:title> Common TNF-&#x003b1;, IL-1&#x003b2;, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Infectious Diseases 7(1): 108-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2334(2007)7:1&#x0003c;108&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2334</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Several studies have investigated single nucleotide polymorphisms (SNPs) in candidate genes associated with sepsis and septic shock with conflicting results. Only few studies have combined the analysis of multiple SNPs in the same population.</p></sec><sec sec-type="methods"><title>Methods</title><p>Clinical data and DNA from consecutive adult patients with culture proven Gram negative bacteremia admitted to a Danish hospital between 2000 and 2002. Analysis for commonly described SNPs of tumor necrosis-&#x003b1;, (TNF-&#x003b1;), interleukin-1&#x003b2; (IL-1&#x003b2;), plasminogen activator-1 (PAI-1), urokinase plasminogen activator (uPA), CD14 and toll-like receptor 4 (TLR4) was done.</p></sec><sec><title>Results</title><p>Of 319 adults, 74% had sepsis, 19% had severe sepsis and 7% were in septic shock. No correlation between severity or outcome of sepsis was observed for the analyzed SNPs of TNF-&#x003b1;, IL-1&#x003b2;, PAI-1, uPA, CD14 or TLR-4. In multivariate Cox proportional hazard regression analysis, increasing age, polymicrobial infection and haemoglobin levels were associated with in-hospital mortality.</p></sec><sec><title>Conclusion</title><p>We did not find any association between TNF-&#x003b1;, IL-1&#x003b2;, PAI-1, uPA, CD14 and TLR4 polymorphisms and outcome of Gram negative sepsis. Other host factors appear to be more important than the genotypes studied here in determining the severity and outcome of Gram negative sepsis.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The syndromes of severe sepsis and septic shock are frequent and associated with high mortality [<xref ref-type="bibr" rid="B1">1</xref>]. Their pathophysiology is complex and results from the interaction between infecting pathogens and inflammatory and coagulation pathways [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. Among the numerous microorganisms that cause sepsis, Gram negative bacteria, predominantly <italic>Enterobacteriacea</italic>, account for one third of all cases [<xref ref-type="bibr" rid="B1">1</xref>].</p><p>Innate host defence is integrally linked to inflammation and coagulation [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Gram negative bacterial lipopolysaccharide (LPS, endotoxin) is sensed by LPS-binding protein (LBP) by the human host. The LPS-LBP complex binds to the cellular surface receptor CD14 and interacts with the toll-like receptor 4 (TLR4) to induce nuclear factor &#x003ba;-B signalling and transcription of cytokines, chemokines, adhesion and coagulation factors [<xref ref-type="bibr" rid="B5">5</xref>]. Among these, tumor necrosis factor &#x003b1; (TNF-&#x003b1;) and interleukin-1&#x003b2; (Il-1&#x003b2;) are decisive proinflammatory mediators. Blood clotting can be initiated by TNF-&#x003b1; and endotoxin and is counteracted by fibrinolysis. Fibrinolysis is initiated by two types of plasminogen activators, the urokinase-type (uPA) and the tissue-type (tPA) and may be inhibited by the plasminogen activator inhibitors, PAI-1 and PAI-2.</p><p>Genetic epidemiologic studies suggest a strong genetic influence on the outcome from sepsis [<xref ref-type="bibr" rid="B6">6</xref>]. Since dysregulation of innate immunity is believed to be central for the manifestations of sepsis, studies of genetic susceptibility to and outcome of septic shock have focused on genes involved in inflammatory and coagulation pathways. Synonymous and non-synonymous single nucleotide polymorphisms (SNPs) may alter the expression or function of transcribed gene products. We included SNPs that had been shown in other studies to have either clinical or experimental relevance with sepsis outcome through the inflammatory and coagulation pathways. Data indicate that SNPs of TNF-&#x003b1; [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>], Il-1&#x003b2; [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>], PAI-1 [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>], and CD14 [<xref ref-type="bibr" rid="B13">13</xref>] may be associated with a poor prognosis from sepsis. Polymorphisms in TLR4 [<xref ref-type="bibr" rid="B14">14</xref>] and CD14 [<xref ref-type="bibr" rid="B13">13</xref>] are further associated with an increased susceptibility to infection. The uPA polymorphism has not previously been studied in sepsis.</p><p>Here we present a genetic association study of Gram negative sepsis with focus on six SNPs previously linked to sepsis pathogenesis and survival.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>All patients older than 17 years admitted to Hvidovre Hospital between June 2000 and May 2002 with a positive blood culture yielding a Gram negative organism were included in the study. Demographic, clinical and laboratory data were extracted on a standardized form. Sepsis, severe sepsis and septic shock were classified according to international guidelines [<xref ref-type="bibr" rid="B2">2</xref>]. The study was approved by the Ethics Committee for Copenhagen and Frederiksberg Counties (01-085/2000). None of the patients were lost to follow-up.</p></sec><sec><title>Deoxyribonucleic Acid Extraction</title><p>1.5 mL of positive blood culture media was lysed with 1.5 mL of 5 M guanidinium-HCl-100 mM Tris (pH 8.0) [<xref ref-type="bibr" rid="B15">15</xref>]. DNA was then extracted with QIAamp mini Spin columns (Qiagen, Hilden, Germany) as described by the manufacturer and stored at -20&#x000b0;C.</p></sec><sec><title>Genotyping</title><p>Primers, probes and restriction enzymes are shown in Table <xref ref-type="table" rid="T1">1</xref>. The TNF-&#x003b1; SNP was analyzed using a Light Cycler (Roche, Basel, Switzerland) as previously described [<xref ref-type="bibr" rid="B16">16</xref>]. Il-1&#x003b2; SNP was analyzed by Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP) analysis and PAI-1 by allele specific PCR as described [<xref ref-type="bibr" rid="B17">17</xref>]. uPA, TLR4, and CD14 were analyzed using a microsphere based assay (Luminex 100, Luminex Corp., Austin, TX). Wild type and mutant allele capture oligonucleotide probes (Table <xref ref-type="table" rid="T1">1</xref>) were synthesized and modified at the 5' terminus (TAG Copenhagen, Denmark) and coupled to carboxylated microspheres as described by Luminex. PCR was performed using a multiplex PCR (Qiagen multiplex PCR kit, Qiagen) with biotin-labelled primers (Table <xref ref-type="table" rid="T1">1</xref>), and conditions included 95&#x000b0;C for 15 min, 40 cycles of 92&#x000b0;C for 30 seconds, 55&#x000b0;C for 30 seconds and 72&#x000b0;C for 60 seconds. Each biotinylated amplicon was denatured at 95&#x000b0;C for 5 min and hybridized at 54&#x000b0;C for 7.5 min. Samples were filtered through a 1.2 &#x003bc;m Durapore filter, washed, resuspended with streptavidin-R-phycoerythrin, incubated for 10 min and then filtered and washed again before being read with a Luminex-100 according to manufacturer's protocol. All genotyping was performed blinded to study details. The TNF-&#x003b1;, uPA, TLR4, and CD14 SNP results obtained by Lighcycler and Luminex analysis were verified by PCR-RFLP with a minimum of 40 randomly selected samples for each SNP [<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B21">21</xref>]. Congruence was found for all samples. IL-1&#x003b2; and PAI-1 SNPs were not assessed by other means.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Primers, probes and restriction enzymes</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Gene</bold></td><td align="left"><bold>SNP</bold></td><td align="left"><bold>Sense primer</bold></td><td align="left"><bold>Antisense primer</bold></td><td align="left"><bold>Probe/restriction enzyme</bold></td></tr></thead><tbody><tr><td align="left">TNF-&#x003b1;</td><td align="left">G- 308 A</td><td align="left">5'-TAGGTTTTGAGGGGCATGGGGAC-3'</td><td align="left">5'- TCTCGGTTTCTTCTCCATCG -3'</td><td align="left">5'-TAGGTTTTGAGGGGCATGGGGAC-3'-fluorescein<break/>5'-LC Red640-GGGTTCAGCCTCCAGGGTCCTACACAC-3'-phosphate</td></tr><tr><td align="left">Il-1&#x003b2;</td><td align="left">C3953T</td><td align="left">5'-CACTCCCAGCTTCATCCCTA-3'</td><td align="left">5'-AGGTGCATCGTGCACATAAG-3'</td><td align="left"><italic>Taq </italic>I</td></tr><tr><td align="left">PAI-1</td><td align="left">4G/5G</td><td align="left">5G allele; 5 ' -GTCTGGACACGTGGGGG-3 ' 4G allele; 5 ' -GTCTGGACACGTGGGGA-3 '</td><td align="left">5 ' -TGCAGCCAGCCACGTGATTGTCTAG-3 '</td><td align="left">None</td></tr><tr><td align="left">uPA</td><td align="left">C 422 T</td><td align="left">5'-biotin-ACTGCAGGAACCCAGACAAC-3'</td><td align="left">5'-AGGGAGGCAGGTAGGAGAAA-3'</td><td align="left">5'-GCCTAAAGC<bold><underline>C</underline></bold>GCTTGTCCAA-3' 5'-GGCCTAAAGC<bold><underline>T</underline></bold>GCTTGTCCAA-3'</td></tr><tr><td align="left">TLR4</td><td align="left">A 896G</td><td align="left">5'-biotin-AGTCCATCGTTTGGTTCTGG-3'</td><td align="left">5'-AATAGTCACACTCACCAGGGAAA-3'</td><td align="left">5'-AGTCAATAATA<bold><underline>T</underline></bold>CATCGAGGTAG-3' 5'-AGTCAATAATA<bold><underline>C</underline></bold>CATCGAGGTAG-3'</td></tr><tr><td align="left">CD14</td><td align="left">C-159T</td><td align="left">5'-biotin-CACCCACCAGAGAAGGCTTA-3'</td><td align="left">5'-ATCACCTCCCCACCTCTCTT-3'</td><td align="left">5'-GGAGGGGG<bold><underline>G</underline></bold>CCGTAACA-3' 5'-GGGAGGGGG<bold><underline>A</underline></bold>CCGTAACAG-3'</td></tr></tbody></table><table-wrap-foot><p>TNF-&#x003b1;: tumor necrosis factor alpha; Il-1&#x003b2;: interleukin-1 beta; PAI-1: plasminogen activator inhibitor 1; uPA: urokinase-type plasminogen activator; TLR4: toll-like receptor 4; CD14: cluster of differentiation 14; A: adenine; T: thymidine; C: cytosine; G: guanine; SNP: single nucleotide polymorphism; LC: light cycler</p></table-wrap-foot></table-wrap></sec><sec><title>Hardy-Weinberg equilibrium (HWE)</title><p>HWE analysis was performed for each SNP by comparing the detected genotype distribution with the theoretical distribution estimated on the basis of the SNP allelic frequencies. P &#x0003e; 0.05 (&#x003c7;<sup>2 </sup>statistics) was considered to indicate equilibrium.</p></sec><sec><title>Statistics</title><p>Genotype distributions were compared using &#x003c7;<sup>2 </sup>statistics. Relative risk (RR) with 95% confidence interval (CI) of in-hospital mortality associated with genotypes and other variables was estimated using Cox proportional hazards regression analysis by forced entry. Each covariate was entered separately and covariates that were associated with disease at the P &#x0003c; 0.1 level were included in the multivariate model. Survival curves were constructed by the method of Kaplan-Meier. The date of diagnosis (baseline) was defined as the date of blood culture. Analysis was performed with SPSS 11.5 (Statistical Package for Social Sciences, Chicago, IL.). Power And Precision 2.00 (Biostat, Englewood, NJ) was used to calculate statistical power to detect changes in survival.</p></sec></sec><sec><title>Results</title><sec><title>Patient characteristics</title><p>From June 2000 through May 2002, 452 consecutive episodes of Gram negative bacteremia were diagnosed among 427 individuals at Hvidovre Hospital. Of these, 319 were a first episode and had DNA collected. There were no statistical significant differences between individuals included and excluded from the present study. The median age was 76 (interquartile range: 61&#x02013;84), 172 (54%) of subjects were women, and 255 (80%) had at least one chronic underlying illness. In most patients the infectious focus was the urinary tract (83%) and the most common Gram negative bacteria were <italic>Escherichia coli </italic>(69%) and <italic>Klebsiella pneumoniae </italic>(11%). Nineteen other Gram negative bacteria accounted for the remaining 20%.</p></sec><sec><title>Genotypes</title><p>Of 319 included specimens, TNF-&#x003b1; was amplifiable in 304, Il-1&#x003b2; in 317, PAI-1 in 316, uPA in 313, TLR4 in 301, and CD14 in 314. All genotypes were in Hardy-Weinberg equilibrium. Distributions are shown in Table <xref ref-type="table" rid="T2">2</xref>.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Association between genotype and disease severity</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Genotype</bold></td><td align="center"><bold>Sepsis (%)</bold></td><td align="center"><bold>Severe sepsis (%)</bold></td><td align="center"><bold>Septic shock (%)</bold></td><td align="center"><bold>All (%)</bold></td><td align="center"><bold>P value</bold></td></tr></thead><tbody><tr><td align="left"><bold>TNF-&#x003b1; </bold>(G-308A)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">GG</td><td align="center">134 (60)</td><td align="center">35 (58)</td><td align="center">13 (65)</td><td align="center">182 (60)</td><td></td></tr><tr><td align="left">GA</td><td align="center">80 (36)</td><td align="center">20 (33)</td><td align="center">6 (30)</td><td align="center">106 (35)</td><td></td></tr><tr><td align="left">AA</td><td align="center">10 (4)</td><td align="center">5 (9)</td><td align="center">1 (5)</td><td align="center">16 (5)</td><td align="center">0.92</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>Il-1&#x003b2; </bold>(C3953T)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">CC</td><td align="center">135 (57)</td><td align="center">32 (53)</td><td align="center">11 (52)</td><td align="center">178 (56)</td><td></td></tr><tr><td align="left">CT</td><td align="center">83 (35)</td><td align="center">24 (40)</td><td align="center">10 (48)</td><td align="center">117 (37)</td><td></td></tr><tr><td align="left">TT</td><td align="center">18 (8)</td><td align="center">4 (7)</td><td align="center">0</td><td align="center">22 (7)</td><td align="center">0.5</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>PAI-1 </bold>(4G/5G)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">4G-4G</td><td align="center">67 (28)</td><td align="center">16 (27)</td><td align="center">7 (33)</td><td align="center">90 (28)</td><td></td></tr><tr><td align="left">4G-5G</td><td align="center">134 (58)</td><td align="center">37 (62)</td><td align="center">12 (57)</td><td align="center">183 (58)</td><td></td></tr><tr><td align="left">5G-5G</td><td align="center">35 (14)</td><td align="center">7 (11)</td><td align="center">2 (10)</td><td align="center">44 (14)</td><td align="center">0.89</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>uPA </bold>(C422T)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">CC</td><td align="center">135 (58)</td><td align="center">41 (67)</td><td align="center">11 (52)</td><td align="center">187 (60)</td><td></td></tr><tr><td align="left">CT</td><td align="center">87 (38)</td><td align="center">19 (31)</td><td align="center">8 (38)</td><td align="center">114 (36)</td><td></td></tr><tr><td align="left">TT</td><td align="center">9 (4)</td><td align="center">1 (2)</td><td align="center">2 (10)</td><td align="center">12 (4)</td><td align="center">0.30</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>TLR4 </bold>(A 896G)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">AA</td><td align="center">204 (91)</td><td align="center">52 (91)</td><td align="center">18 (86)</td><td align="center">274 (91)</td><td></td></tr><tr><td align="left">AG</td><td align="center">19 (9)</td><td align="center">5 (9)</td><td align="center">3 (14)</td><td align="center">27 (9)</td><td></td></tr><tr><td align="left">GG</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0</td><td align="center">0.52</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>CD14 </bold>(C-159T)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">CC</td><td align="center">72 (31)</td><td align="center">13 (22)</td><td align="center">7 (33)</td><td align="center">92 (29)</td><td></td></tr><tr><td align="left">CT</td><td align="center">117 (50)</td><td align="center">30 (51)</td><td align="center">9 (43)</td><td align="center">156 (50)</td><td></td></tr><tr><td align="left">TT</td><td align="center">45 (19)</td><td align="center">16 (27)</td><td align="center">5 (24)</td><td align="center">66 (21)</td><td align="center">0.57</td></tr></tbody></table><table-wrap-foot><p>TNF-&#x003b1;: tumor necrosis factor alpha; Il-1&#x003b2;: interleukin-1 beta; PAI-1: plasminogen activator inhibitor 1; uPA: urokinase-type plasminogen activator; TLR4: toll-like receptor 4; CD14: cluster of differentiation 14; A: adenine; T: thymidine; C: cytosine; G: guanine</p></table-wrap-foot></table-wrap></sec><sec><title>Genotypes and baseline characteristics</title><p>No associations were found between genotypes and demographics (age, sex, and comorbidity), temperature, mean arterial blood pressure, white blood cell count, C-reactive protein or causative organism at the time of blood culture.</p></sec><sec><title>Disease severity and genotype</title><p>The majority of patients met the criteria for sepsis at the time of blood culture (74%). 19% met the criteria for severe sepsis and 7% were in septic shock.</p><p>Neither TNF-&#x003b1;, Il-1&#x003b2;, PAI-1, uPA, TLR4, nor CD14 SNPs were associated with disease severity.</p></sec><sec><title>Mortality and genotype</title><p>In total 63 (19%) died during hospitalization. Mortality increased with severity of disease from 17% for sepsis to 25% and 38% for severe sepsis and septic shock, respectively (Figure <xref ref-type="fig" rid="F1">1</xref>). We did not detect any association between the tested SNPs and outcome (in-hospital, 1 or 3 month mortality rates) when tested for the whole group or tested for each of the severity groups (Table <xref ref-type="table" rid="T3">3</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>90-day survival from Gram negative sepsis according to disease severity. Log-rank test: P = 0.014.</p></caption><graphic xlink:href="1471-2334-7-108-1"/></fig><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>In-hospital mortality according to genotype</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Genotype</bold></td><td align="center"><bold>In-hospital mortality (%)</bold></td><td align="center"><bold>P value</bold></td></tr></thead><tbody><tr><td align="left"><bold>TNF-&#x003b1; </bold>(G-308A)</td><td/><td></td></tr><tr><td align="left">GG</td><td align="center">34/182 (19)</td><td></td></tr><tr><td align="left">GA</td><td align="center">20/106 (19)</td><td></td></tr><tr><td align="left">AA</td><td align="center">6/16 (38)</td><td align="center">0.19</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>Il-1&#x003b2; </bold>(C3953T)</td><td></td><td></td></tr><tr><td align="left">CC</td><td align="center">32/178 (18)</td><td></td></tr><tr><td align="left">CT</td><td align="center">25/117 (21)</td><td></td></tr><tr><td align="left">TT</td><td align="center">5/22 (23)</td><td align="center">0.61</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>PAI-1 </bold>(4G/5G)</td><td></td><td></td></tr><tr><td align="left">4G-4G</td><td align="center">15/90 (17)</td><td></td></tr><tr><td align="left">4G-5G</td><td align="center">37/183 (20)</td><td></td></tr><tr><td align="left">5G-5G</td><td align="center">11/44 (25)</td><td align="center">0.61</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>uPA </bold>(C422T)</td><td></td><td></td></tr><tr><td align="left">CC</td><td align="center">40/187 (21)</td><td></td></tr><tr><td align="left">CT</td><td align="center">20/114 (18)</td><td></td></tr><tr><td align="left">TT</td><td align="center">2/12 (17)</td><td align="center">0.86</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>TLR4 </bold>(A 896G)</td><td></td><td></td></tr><tr><td align="left">AA</td><td align="center">49/274 (18)</td><td></td></tr><tr><td align="left">AG</td><td align="center">8/27 (30)</td><td></td></tr><tr><td align="left">GG</td><td align="center">-</td><td align="center">0.11</td></tr><tr><td colspan="3"><hr></hr></td></tr><tr><td align="left"><bold>CD14 </bold>(C-159T)</td><td></td><td></td></tr><tr><td align="left">CC</td><td align="center">18/92 (20)</td><td></td></tr><tr><td align="left">CT</td><td align="center">33/156 (21)</td><td></td></tr><tr><td align="left">TT</td><td align="center">11/66 (17)</td><td align="center">0.90</td></tr></tbody></table><table-wrap-foot><p>TNF-&#x003b1;: tumor necrosis factor alpha; Il-1&#x003b2;: interleukin-1 beta; PAI-1: plasminogen activator inhibitor 1; uPA: urokinase-type plasminogen activator; TLR4: toll-like receptor 4; CD14: cluster of differentiation 14; A: adenine; T: thymidine; C: cytosine; G: guanine</p></table-wrap-foot></table-wrap></sec><sec><title>Multivariate analysis of factors associated with outcome</title><p>A possible association of genotypes and other baseline variables with in-hospital mortality was further explored by Cox regression analysis. By univariate analysis, increasing age, disease severity, polymicrobial infection, intensive care admission, lower haemoglobin, leukocytosis, elevated C-reactive protein, elevated plasma urea, and elevated alanine transferase was associated with in-hospital mortality. Sex, comorbidity, alcoholism, mean arterial pressure, temperature, lymphocyte count, platelet count, bilirubin and lactate dehydrogenase was not associated with in-hospital mortality. Variables were then grouped in two categories due to the many covariates associated with mortality in univariate analysis relative to the number of events and, thereby, the risk of overfitting the multivariate analysis. Model 1 consisted of demographic variables and microbiological findings and model 2 consisted of laboratory values. Variables associated with in-hospital mortality at P &#x0003c; 0.05 were then fitted in a third model. By this approach, increasing age and polymicrobial infection was associated with a poor outcome, whereas increasing haemoglobin levels were associated with a better outcome (Table <xref ref-type="table" rid="T4">4</xref>). Finally, based on this analysis, we stratified for polymicrobial infection and/or entered age and/or haemoglobin levels in the Cox analysis in order to investigate whether SNPs affected outcome in subgroups of patients with Gram negative sepsis. None of the SNPs were associated with outcome.</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Multivariate analysis of factors associated with in-hospital mortality</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2"><bold>Model 1</bold></td><td align="center" colspan="2"><bold>Model 2</bold></td><td align="left" colspan="2"><bold>Model 3</bold></td></tr></thead><tbody><tr><td align="left"><bold>Variable</bold></td><td align="center">RR (95% CI)</td><td align="left">P value</td><td align="center">RR (95% CI)</td><td align="left">P value</td><td align="left">RR (95% CI)</td><td align="left">P value</td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Age, per year increment</bold></td><td align="center">1.02 (1.00&#x02013;1.04)</td><td align="left">0.026</td><td align="center">-</td><td></td><td align="left">1.02 (1.00&#x02013;1.03)</td><td align="left">0.053</td></tr><tr><td align="left"><bold>Diseases severity</bold></td><td></td><td></td><td align="center">-</td><td></td><td align="left">-</td><td></td></tr><tr><td align="left">&#x02003;Sepsis</td><td align="center">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Severe sepsis</td><td align="center">1.25 (0.65&#x02013;2.39)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Septic shock</td><td align="center">1.70 (0.48&#x02013;6.05)</td><td align="left">0.674</td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>Intensive care admission</bold></td><td></td><td></td><td align="center">-</td><td></td><td align="left">-</td><td></td></tr><tr><td align="left">No</td><td align="center">1.0</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Yes</td><td align="center">2.50 (0.85&#x02013;7.42)</td><td align="left">0.098</td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold>Polymicrobial infection</bold></td><td></td><td></td><td align="center">-</td><td></td><td></td><td></td></tr><tr><td align="left">No</td><td align="center">1.0</td><td></td><td></td><td></td><td align="left">1.0</td><td></td></tr><tr><td align="left">Yes</td><td align="center">3.02 (1.58&#x02013;7.41)</td><td align="left">0.001</td><td></td><td></td><td align="left">2.52 (1.27&#x02013;5.01)</td><td align="left">0.008</td></tr><tr><td align="left"><bold>Hemoglobin, per &#x003bc;mol/L increase</bold></td><td align="center">-</td><td></td><td align="center">0.71 (0.52&#x02013;0.97)</td><td align="left">0.031</td><td align="left">0.70 (0.56&#x02013;0.88)</td><td align="left">0.002</td></tr><tr><td align="left"><bold>Leukocyte count, per 10</bold><sup>9</sup><bold>/mL increase</bold></td><td align="center">-</td><td></td><td align="center">1.00 (0.96&#x02013;1.05)</td><td align="left">0.795</td><td align="left">-</td><td></td></tr><tr><td align="left"><bold>C-reactive protein, per milligram/L increase</bold></td><td align="center">-</td><td></td><td align="center">1.00 (0.99&#x02013;1.00)</td><td align="left">0.287</td><td align="left">-</td><td></td></tr><tr><td align="left"><bold>Urea, per &#x003bc;mol/L increase</bold></td><td align="center">-</td><td></td><td align="center">1.02 (0.98&#x02013;1.06)</td><td align="left">0.234</td><td align="left">-</td><td></td></tr><tr><td align="left"><bold>Alanine transferase, per unit/L increase</bold></td><td align="center">-</td><td></td><td align="center">0.99 (0.98&#x02013;1.00)</td><td align="left">0.195</td><td align="left">-</td><td></td></tr></tbody></table><table-wrap-foot><p>RR: relative risk; CI: confidence interval</p></table-wrap-foot></table-wrap></sec></sec><sec><title>Discussion</title><p>We did not find any association between disease severity and putative SNPs involved in inflammatory and coagulation pathways during the course of sepsis nor were any of the SNPs associated with outcome. The homozygous TNF-&#x003b1; AA and heterozygous TLR4 AG SNPs were associated with an increased but statistically non-significant risk of death.</p><p>Genetic association studies notoriously contradict one another [<xref ref-type="bibr" rid="B22">22</xref>]. Conflicting results have been reported for TNF-&#x003b1; (G-308A), which was associated to disease severity and outcome in some [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B23">23</xref>] but not other studies [<xref ref-type="bibr" rid="B24">24</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. Controversy also exists regarding the role of for PAI-1 [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B27">27</xref>], CD14 (C-159T) [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B28">28</xref>], TLR4 (A896G) [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B29">29</xref>], although IL-1&#x003b2; (C3953T) have consistently been reported to be without association to disease severity or outcome [<xref ref-type="bibr" rid="B30">30</xref>]. Methological problems may explain many of the discrepancies. In particular, many studies have insufficient sample size to make firm statistical conclusions. The present study provided &#x0003e; 80% power to detect a 1.5-fold increase in relative risk of death for the heterozygous forms of TNF-&#x003b1;, Il-1&#x003b2;, PAI-1, uPA, and CD14, while a 2.5-fold was necessary to provide 80% power to detect differences associated with the lesser frequent allele frequencies of TLR4. Although, the level of association may be debated, we find 1.5&#x02013;2.5-fold changes reasonable. The study was, however, underpowered to detect associations with the lesser frequent homozygous TNF-&#x003b1;, IL-1&#x003b2;, uPA and heterozygous TLR4 genotypes. Publication bias may also influence the true genetic association between disease severity and outcome because negative association studies are less likely to be published than studies that find an association. Our negative findings may be due to the fact that our population differs from the previous reported studies showing a positive correlation, e.g. studies of meningococcal disease alone (PAI-1, TLR4 and TNF-&#x003b1;) and of patients with severe sepsis in intensive care settings (TNF-&#x003b1; and TLR4).</p><p>Strengths of the present study include the fact that the cohort represents unselected and consecutive patients with Gram negative sepsis. Limitations relate to the sample size because larger samples would detect smaller associations than studied here. Meta-analysis of multiple cohorts could add power to discriminate between potential genetic associations and statistical uncertainties of polymorphisms of genes in the inflammatory and coagulative pathways. Use of novel technologies that permit genome-wide genetic analysis of SNPs and haplotypes will likely be useful in future genetic association studies.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>KMJ, SBL, and ALP developed and performed the genetic analysis. JEO and TB were responsible for conception, design, data collection and statistical analysis. All authors participated in the writing of the manuscript. All authors have read and approved the final version of the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2334/7/108/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Funding: Danish Medical Association Research Fund; Danish Hospital Foundation for Medical Research; Region of Copenhagen, the Faroe Islands and Greenland; Copenhagen Hospital Corporation Research Fund; and the A.P. M&#x000f8;ller Foundation for the Advancement of Medical Science.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>GS</given-names></name><name><surname>Mannino</surname><given-names>GM</given-names></name><name><surname>Eaton</surname><given-names>S</given-names></name><name><surname>Moss</surname><given-names>M</given-names></name></person-group><article-title>The epidemiology of sepsis in the United States from 1979 through 2000</article-title><year>2003</year><volume>348</volume><fpage>1546</fpage><lpage>1554</lpage><pub-id pub-id-type="pmid">12700374</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bone</surname><given-names>RC</given-names></name><name><surname>Balk</surname><given-names>RA</given-names></name><name><surname>Cerra</surname><given-names>FB</given-names></name><name><surname>Dellinger</surname><given-names>RP</given-names></name><name><surname>Fein</surname><given-names>AM</given-names></name><name><surname>Knaus</surname><given-names>WA</given-names></name><name><surname>Schein</surname><given-names>RM</given-names></name><name><surname>Sibbald</surname><given-names>WJ</given-names></name></person-group><article-title>Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine</article-title><source>Chest</source><year>1992</year><volume>101</volume><fpage>1644</fpage><lpage>1655</lpage><pub-id pub-id-type="pmid">1303622</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>JA</given-names></name></person-group><article-title>Management of sepsis</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>1699</fpage><lpage>1713</lpage><pub-id pub-id-type="pmid">17050894</pub-id><pub-id pub-id-type="doi">10.1056/NEJMra043632</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esmon</surname><given-names>CT</given-names></name></person-group><article-title>Interactions between the innate immune and blood coagulation systems</article-title><source>Trends Immunol</source><year>2004</year><volume>25</volume><fpage>536</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">15364056</pub-id><pub-id pub-id-type="doi">10.1016/j.it.2004.08.003</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beutler</surname><given-names>B</given-names></name><name><surname>Hoebe</surname><given-names>K</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Ulevitch</surname><given-names>RJ</given-names></name></person-group><article-title>How we detect microbes and respond to them: the Toll-like receptors and their transducers</article-title><source>J Leukoc Biol</source><year>2003</year><volume>74</volume><fpage>479</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">12960260</pub-id><pub-id pub-id-type="doi">10.1189/jlb.0203082</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sorensen</surname><given-names>TI</given-names></name><name><surname>Nielsen</surname><given-names>GG</given-names></name><name><surname>Andersen</surname><given-names>PK</given-names></name><name><surname>Teasdale</surname><given-names>TW</given-names></name></person-group><article-title>Genetic and environmental influences on premature death in adult adoptees</article-title><source>N Engl J Med</source><year>1988</year><volume>318</volume><fpage>727</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">3347221</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nadel</surname><given-names>S</given-names></name><name><surname>Newport</surname><given-names>MJ</given-names></name><name><surname>Booy</surname><given-names>R</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name></person-group><article-title>Variation in the tumor necrosis factor-a gene promoter region may be associated with death from meningococcal disease.</article-title><source>J Infect Dis</source><year>1996</year><volume>174</volume><fpage>878</fpage><lpage>880</lpage><pub-id pub-id-type="pmid">8843235</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mira</surname><given-names>JP</given-names></name><name><surname>Cariou</surname><given-names>A</given-names></name><name><surname>Grall</surname><given-names>F</given-names></name><name><surname>Delclaux</surname><given-names>C</given-names></name><name><surname>Losser</surname><given-names>MR</given-names></name><name><surname>Heshmati</surname><given-names>F</given-names></name><name><surname>Cheval</surname><given-names>C</given-names></name><name><surname>Monchi</surname><given-names>M</given-names></name><name><surname>Teboul</surname><given-names>JL</given-names></name><name><surname>Riche</surname><given-names>F</given-names></name><name><surname>Leleu</surname><given-names>G</given-names></name><name><surname>Arbibe</surname><given-names>L</given-names></name><name><surname>Mignon</surname><given-names>A</given-names></name><name><surname>Delpech</surname><given-names>M</given-names></name><name><surname>Dhainaut</surname><given-names>JF</given-names></name></person-group><article-title>Association of TNF2, a TNF-a promoter polymorphism, with septic shock susceptibility and mortality.</article-title><source>JAMA</source><year>1999</year><volume>282</volume><fpage>561</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">10450718</pub-id><pub-id pub-id-type="doi">10.1001/jama.282.6.561</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pociot</surname><given-names>F</given-names></name><name><surname>Molvig</surname><given-names>J</given-names></name><name><surname>Wogensen</surname><given-names>L</given-names></name><name><surname>Worsaae</surname><given-names>H</given-names></name><name><surname>Nerup</surname><given-names>J</given-names></name></person-group><article-title>A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro</article-title><source>Eur J Clin Invest</source><year>1992</year><volume>22</volume><fpage>396</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">1353022</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walley</surname><given-names>AJ</given-names></name><name><surname>Aucan</surname><given-names>C</given-names></name><name><surname>Kwiatkowski</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name></person-group><article-title>Interleukin-1 gene cluster polymorphisms and susceptibility to clinical malaria in a Gambian case-control study</article-title><source>Eur J Hum Genet</source><year>2004</year><volume>12</volume><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">14673470</pub-id><pub-id pub-id-type="doi">10.1038/sj.ejhg.5201084</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermans</surname><given-names>PW</given-names></name><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Booy</surname><given-names>R</given-names></name><name><surname>Daramola</surname><given-names>O</given-names></name><name><surname>Hazelzet</surname><given-names>JA</given-names></name><name><surname>de Groot</surname><given-names>R</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name></person-group><article-title>4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group.</article-title><source>Lancet</source><year>1999</year><volume>354</volume><fpage>556</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">10470700</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(99)02220-5</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Westendorp</surname><given-names>RG</given-names></name><name><surname>Hottenga</surname><given-names>JJ</given-names></name><name><surname>Slagboom</surname><given-names>PE</given-names></name></person-group><article-title>Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock.</article-title><source>Lancet</source><year>1999</year><volume>354</volume><fpage>561</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">10470701</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(98)09376-3</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gibot</surname><given-names>S</given-names></name><name><surname>Cariou</surname><given-names>A</given-names></name><name><surname>Drouet</surname><given-names>L</given-names></name><name><surname>Rossignol</surname><given-names>M</given-names></name><name><surname>Ripoll</surname><given-names>L</given-names></name></person-group><article-title>Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>969</fpage><lpage>973</lpage><pub-id pub-id-type="pmid">12006789</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200205000-00003</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smirnova</surname><given-names>I</given-names></name><name><surname>Mann</surname><given-names>N</given-names></name><name><surname>Dols</surname><given-names>A</given-names></name><name><surname>Derkx</surname><given-names>HH</given-names></name><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name><name><surname>Beutler</surname><given-names>B</given-names></name></person-group><article-title>Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><pub-id pub-id-type="pmid">12730365</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fredricks</surname><given-names>DN</given-names></name><name><surname>Relman</surname><given-names>DA</given-names></name></person-group><article-title>Improved amplification of microbial DNA from blood cultures by removal of the PCR inhibitor sodium polyanetholesulfonate.</article-title><source>J Clin Microbiol</source><year>1998</year><volume>36</volume><fpage>2810</fpage><lpage>2816</lpage><pub-id pub-id-type="pmid">9738025</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bruunsgaard</surname><given-names>H</given-names></name><name><surname>Benfield</surname><given-names>TL</given-names></name><name><surname>Andersen-Ranberg</surname><given-names>K</given-names></name><name><surname>Hjelmborg Jv</surname><given-names>JB</given-names></name><name><surname>Pedersen</surname><given-names>AN</given-names></name><name><surname>Schroll</surname><given-names>M</given-names></name><name><surname>Pedersen</surname><given-names>BK</given-names></name><name><surname>Jeune</surname><given-names>B</given-names></name></person-group><article-title>The Tumor Necrosis Factor Alpha -308G&#x0003e;A Polymorphism Is Associated with Dementia in the Oldest Old</article-title><source>J Am Geriatr Soc</source><year>2004</year><volume>52</volume><fpage>1361</fpage><lpage>1366</lpage><pub-id pub-id-type="pmid">15271127</pub-id><pub-id pub-id-type="doi">10.1111/j.1532-5415.2004.52369.x</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Margaglione</surname><given-names>M</given-names></name><name><surname>Grandone</surname><given-names>E</given-names></name><name><surname>Cappucci</surname><given-names>G</given-names></name><name><surname>Colaizzo</surname><given-names>D</given-names></name><name><surname>Giuliani</surname><given-names>N</given-names></name><name><surname>Vecchione</surname><given-names>G</given-names></name><name><surname>d'Addedda</surname><given-names>M</given-names></name><name><surname>Di</surname><given-names>MG</given-names></name></person-group><article-title>An alternative method for PAI-1 promoter polymorphism (4G/5G) typing</article-title><source>Thromb Haemost</source><year>1997</year><volume>77</volume><fpage>605</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">9066021</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>AG</given-names></name><name><surname>di Giovine</surname><given-names>FS</given-names></name><name><surname>Blakemore</surname><given-names>AIF</given-names></name><name><surname>Duff</surname><given-names>GW</given-names></name></person-group><article-title>Single base polymorphism in the human tumour necrosis factor a (TNFa) gene detectable by NcoI restriction of PCR product.</article-title><source>Hum Mol Genet</source><year>1992</year><volume>1</volume><fpage>353</fpage><pub-id pub-id-type="pmid">1363876</pub-id><pub-id pub-id-type="doi">10.1093/hmg/1.5.353</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baldini</surname><given-names>M</given-names></name><name><surname>Lohman</surname><given-names>IC</given-names></name><name><surname>Halonen</surname><given-names>M</given-names></name><name><surname>Erickson</surname><given-names>RP</given-names></name><name><surname>Holt</surname><given-names>PG</given-names></name><name><surname>Martinez</surname><given-names>FD</given-names></name></person-group><article-title>A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E</article-title><source>Am J Respir Cell Mol Biol</source><year>1999</year><volume>20</volume><fpage>976</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">10226067</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>E</given-names></name><name><surname>Mira</surname><given-names>JP</given-names></name><name><surname>Frees</surname><given-names>KL</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name></person-group><article-title>Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock</article-title><source>Arch Intern Med</source><year>2002</year><volume>162</volume><fpage>1028</fpage><lpage>1032</lpage><pub-id pub-id-type="pmid">11996613</pub-id><pub-id pub-id-type="doi">10.1001/archinte.162.9.1028</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beqaj</surname><given-names>SH</given-names></name><name><surname>Post</surname><given-names>D</given-names></name><name><surname>Ryan</surname><given-names>JM</given-names></name></person-group><article-title>Single-nucleotide polymorphism of the urokinase-plasminogen activator gene during aging and transformation of human diploid kidney cell cultures</article-title><source>In Vitro Cell Dev Biol Anim</source><year>2003</year><volume>39</volume><fpage>343</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">14686874</pub-id><pub-id pub-id-type="doi">10.1290/1543-706X(2003)039&#x0003c;0343:SPOTUA&#x0003e;2.0.CO;2</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>MF</given-names></name><name><surname>Baudouin</surname><given-names>SV</given-names></name></person-group><article-title>A systematic review of the quality of genetic association studies in human sepsis</article-title><source>Intensive Care Med</source><year>2006</year><volume>32</volume><fpage>1706</fpage><lpage>1712</lpage><pub-id pub-id-type="pmid">16957907</pub-id><pub-id pub-id-type="doi">10.1007/s00134-006-0327-y</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>GJ</given-names></name><name><surname>Huang</surname><given-names>SL</given-names></name><name><surname>Yien</surname><given-names>HW</given-names></name><name><surname>Chen</surname><given-names>WS</given-names></name><name><surname>Chi</surname><given-names>CW</given-names></name><name><surname>Wu</surname><given-names>CW</given-names></name><name><surname>Lui</surname><given-names>WY</given-names></name><name><surname>Chiu</surname><given-names>JH</given-names></name><name><surname>Lee</surname><given-names>TY</given-names></name></person-group><article-title>Tumor necrosis factor gene polymorphism and septic shock in surgical infection</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><fpage>2733</fpage><lpage>2736</lpage><pub-id pub-id-type="pmid">10966243</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200008000-00008</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stuber</surname><given-names>F</given-names></name><name><surname>Udalova</surname><given-names>IA</given-names></name><name><surname>Book</surname><given-names>M</given-names></name><name><surname>Drutskaya</surname><given-names>LN</given-names></name><name><surname>Kuprash</surname><given-names>DV</given-names></name><name><surname>Turetskaya</surname><given-names>RL</given-names></name><name><surname>Schade</surname><given-names>FU</given-names></name><name><surname>Nedospasov</surname><given-names>SA</given-names></name></person-group><article-title>-308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter</article-title><source>J Inflamm</source><year>1995</year><volume>46</volume><fpage>42</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">8832971</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>CL</given-names></name><name><surname>Perrey</surname><given-names>C</given-names></name><name><surname>Pravica</surname><given-names>V</given-names></name><name><surname>Hutchinson</surname><given-names>IV</given-names></name><name><surname>Campbell</surname><given-names>IT</given-names></name></person-group><article-title>Genetic variation in proinflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome</article-title><source>Crit Care Med</source><year>2002</year><volume>30</volume><fpage>2216</fpage><lpage>2221</lpage><pub-id pub-id-type="pmid">12394947</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200210000-00007</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>AC</given-names></name><name><surname>Lagan</surname><given-names>AL</given-names></name><name><surname>Aganna</surname><given-names>E</given-names></name><name><surname>Cheung</surname><given-names>L</given-names></name><name><surname>Peters</surname><given-names>CJ</given-names></name><name><surname>McDermott</surname><given-names>MF</given-names></name><name><surname>Millo</surname><given-names>JL</given-names></name><name><surname>Welsh</surname><given-names>KI</given-names></name><name><surname>Holloway</surname><given-names>P</given-names></name><name><surname>Hitman</surname><given-names>GA</given-names></name><name><surname>Piper</surname><given-names>RD</given-names></name><name><surname>Garrard</surname><given-names>CS</given-names></name><name><surname>Hinds</surname><given-names>CJ</given-names></name></person-group><article-title>TNF and TNFR polymorphisms in severe sepsis and septic shock: a prospective multicentre study</article-title><source>Genes Immun</source><year>2004</year><volume>5</volume><fpage>631</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">15526005</pub-id><pub-id pub-id-type="doi">10.1038/sj.gene.6364136</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haralambous</surname><given-names>E</given-names></name><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Hermans</surname><given-names>PW</given-names></name><name><surname>Ninis</surname><given-names>N</given-names></name><name><surname>Nadel</surname><given-names>S</given-names></name><name><surname>Levin</surname><given-names>M</given-names></name></person-group><article-title>Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><fpage>2788</fpage><lpage>2793</lpage><pub-id pub-id-type="pmid">14668616</pub-id><pub-id pub-id-type="doi">10.1097/01.CCM.0000100122.57249.5D</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hubacek</surname><given-names>JA</given-names></name><name><surname>Stuber</surname><given-names>F</given-names></name><name><surname>Frohlich</surname><given-names>D</given-names></name><name><surname>Book</surname><given-names>M</given-names></name><name><surname>Wetegrove</surname><given-names>S</given-names></name><name><surname>Rothe</surname><given-names>G</given-names></name><name><surname>Schmitz</surname><given-names>G</given-names></name></person-group><article-title>The common functional C(-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality</article-title><source>Genes Immun</source><year>2000</year><volume>1</volume><fpage>405</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">11196689</pub-id><pub-id pub-id-type="doi">10.1038/sj.gene.6363691</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>RC</given-names></name><name><surname>Pullin</surname><given-names>J</given-names></name><name><surname>Gregory</surname><given-names>S</given-names></name><name><surname>Borrow</surname><given-names>R</given-names></name><name><surname>Kaczmarski</surname><given-names>EB</given-names></name><name><surname>di Giovine</surname><given-names>FS</given-names></name><name><surname>Dower</surname><given-names>SK</given-names></name><name><surname>Cannings</surname><given-names>C</given-names></name><name><surname>Wilson</surname><given-names>AG</given-names></name></person-group><article-title>A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease</article-title><source>J Infect Dis</source><year>2001</year><volume>184</volume><fpage>640</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">11494169</pub-id><pub-id pub-id-type="doi">10.1086/322798</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>XM</given-names></name><name><surname>Schroder</surname><given-names>S</given-names></name><name><surname>Hoeft</surname><given-names>A</given-names></name><name><surname>Stuber</surname><given-names>F</given-names></name></person-group><article-title>Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis</article-title><source>Crit Care Med</source><year>1999</year><volume>27</volume><fpage>1330</fpage><lpage>1334</lpage><pub-id pub-id-type="pmid">10446828</pub-id><pub-id pub-id-type="doi">10.1097/00003246-199907000-00024</pub-id></citation></ref></ref-list></back></article> 